Immunology Service, Professor Edgard Santos University Hospital Complex, Federal University of Bahia, Salvador, Bahia, Brazil.
Published: February 2023
AI Article Synopsis
Article Abstract
Dogs living in areas of Leishmania (Viannia) braziliensis transmission may present canine tegumentary leishmaniasis (CTL) characterized by cutaneous or muzzle ulcers as well as asymptomatic L. braziliensis infection. It is not clear if dogs participate in the transmission chain of L. braziliensis to humans. However, dogs may remain with chronic ulcers for a long time, and as there are no public policies about CTL, these animals die or are sacrificed. Here we compare the efficacy of intralesional meglumine antimoniate with intralesional 0.9% NaCl solution in CTL treatment. This randomized control study included 32 dogs with cutaneous or muzzle lesions who had L. braziliensis DNA detected by PCR in tissue biopsied. Group one received 5ml of intralesional Glucantime, and group two received 5ml 0.9% NaCl solution, both applied in the four cardinal points on days 0, 15, and 30. Cure was defined as complete healing of the ulcers in the absence of raised borders on day 90. There was no difference in animals' demographic and clinical features in the two groups (p >.05). While at the endpoint, the cure rate was 87.5% in the group test, and in those who received 0.9 NaCl the cure rate was only 12.5%. As important as the high cure rate, the healing time was faster in dogs treated with antimony than in those treated with saline (p < .001). Intralesional meglumine antimoniate is effective in the treatment of dogs with L. braziliensis infection and accelerates the healing time of CTL.
We describe a group of four travelers returning to the United States and Canada who acquired infection in the Peruvian Amazon. Pentavalent antimonials are the preferred treatment option for cutaneous leishmaniasis (CL) in most endemic countries in Central and South America. However, we initially treated our patients with liposomal amphotericin B (LAB) and miltefosine since these are the only two available Food and Drug Administration approved drugs in the United States.
Department of Parasitology and Mycology, Skin Diseases and Leishmaniasis Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Background: Cutaneous leishmaniasis (CL) infection is caused by the parasite and affects 1.5 to 2 million people worldwide each year. Although research into vaccines and antiparasitic drugs has been somewhat successful, their adverse effects include high toxicity, prolonged regeneration, and scarring.
Universidad Autónoma de Campeche, Centro de Investigaciones Biomédicas, Laboratorio de Enfermedades Transmitidas por Vectores y Zoonosis, Campeche, Campeche, Mexico.
Cutaneous leishmaniasis accounts for 99% of leishmaniasis cases in Mexico and typically affects people in rural areas, but a case in Campeche State marks a first for urban transmission.*
-
A 75-year-old man was misdiagnosed with a bacterial infection before a skin lesion on his ear was identified as leishmaniasis, confirmed through tissue testing that detected Leishmania amastigotes.*
-
The case highlights the need for awareness of leishmaniasis in urban settings and signals a shift in understanding its transmission in non-endemic areas of Mexico.*
- Cutaneous leishmaniasis (CL) is a neglected tropical disease with very few cases reported in Côte d'Ivoire since its identification in 1967, highlighting a significant gap in awareness and diagnosis.
- A recent case involved a 15-year-old male with skin lesions and accompanying symptoms, which was confirmed as CL through a biopsy, but he sadly passed away before treatment could be administered.
- The rarity of CL in Côte d'Ivoire leads to low awareness among healthcare professionals, necessitating urgent strategies for better education on diagnosis and treatment, along with the need for improved epidemiological data.
